How Much Does Vyleesi (Bremelanotide) Cost in Indiana in 2026?

Brand-Name Vyleesi Pricing in Indiana

The retail price for Vyleesi in Indiana averages $1,200 per month for eight single-dose auto-injectors. That figure tracks closely with the national average wholesale price (AWP) because Vyleesi has no generic bioequivalent and Palatin Technologies sets a uniform list price across all U.S. Markets 1.

Why the Price Stays Flat Statewide

Indiana has no state-level drug price cap for non-Medicaid prescriptions. Retail pharmacies in Indianapolis, Fort Wayne, and Evansville report nearly identical cash-pay figures because they purchase from the same wholesale tier. Coupon aggregators may show slightly lower estimates, but confirmed fill prices remain close to $1,200.

How That Compares Nationally

Vyleesi pricing does not vary much by geography. The FDA-approved labeling specifies a single 1.75 mg subcutaneous dose used as needed, so there is no weight-based or titration-driven cost variance [1]. A 2023 cost-effectiveness analysis published in the Journal of Managed Care & Specialty Pharmacy noted that bremelanotide's per-dose expense remains a barrier to broader utilization even among commercially insured women 2.

Indiana Medicaid and Vyleesi

Indiana Medicaid does not cover Vyleesi for hypoactive sexual desire disorder (HSDD). The Indiana Health Coverage Programs formulary classifies bremelanotide as non-preferred with no active prior-authorization pathway for HSDD in premenopausal women.

The Formulary Gap

This exclusion is consistent with most state Medicaid programs. A 2020 analysis in Obstetrics & Gynecology found that fewer than 10% of Medicaid formularies listed any FDA-approved HSDD therapy within 12 months of approval 3. Indiana's Healthy Indiana Plan (HIP 2.0) follows CMS guidelines that permit but do not require coverage of drugs for sexual dysfunction 4.

What Medicaid Enrollees Can Do

Patients on Indiana Medicaid have two realistic options. First, appeal through the exceptions process using clinical documentation of HSDD diagnosis per ISSWSH criteria 5. Second, pursue compounded bremelanotide (discussed below), which falls outside formulary restrictions because it is dispensed under a patient-specific prescription from a 503A pharmacy.

Commercial Insurance Coverage in Indiana

Several major commercial plans operating in Indiana place Vyleesi on specialty tiers with prior authorization. Anthem Blue Cross Blue Shield of Indiana, UnitedHealthcare, and CareSource each require a documented HSDD diagnosis, failure of behavioral interventions, and confirmation that the patient is premenopausal 6.

Prior Authorization Requirements

Typical PA criteria across Indiana insurers include: HSDD diagnosis using the DSMI-5 definition of persistently reduced sexual desire causing distress; documented trial of psychotherapy or counseling; no concurrent use of flibanserin; and an FSFI score below a plan-specific threshold. The RECONNECT trials used the Female Sexual Function Index (FSFI) as a co-primary endpoint, and most insurers reference that same instrument 3.

Copay After Approval

When approved, specialty-tier copays in Indiana range from $75 to $250 per fill depending on the plan design. Patients with high-deductible health plans (HDHPs) may owe the full $1,200 until reaching their deductible. The Palatin Technologies savings card can offset some of this cost for commercially insured patients 7.

Compounded Bremelanotide in Indiana

Compounded bremelanotide is available in Indiana through licensed 503A compounding pharmacies at roughly $140 per month. That is an 88% reduction compared to brand Vyleesi.

Legal Framework

Under FDA guidance and Indiana Board of Pharmacy rules, a 503A pharmacy may compound bremelanotide from bulk pharmaceutical-grade active ingredient when a licensed prescriber writes a patient-specific prescription 8. The compound is not a generic; it is a pharmacy-prepared formulation that has not undergone the same clinical trial evaluation as brand Vyleesi. The FDA's 2019 approval of Vyleesi established bremelanotide's safety and efficacy profile at the 1.75 mg subcutaneous dose 1, but compounded versions are not FDA-approved products.

How to Access Compounded Bremelanotide

A prescriber (physician, NP, or PA licensed in Indiana) writes a prescription specifying bremelanotide 1.75 mg subcutaneous injection. The patient fills it at a 503A pharmacy licensed in Indiana or in a state that ships to Indiana. Telehealth prescribing is permitted, which expands access for patients outside Indianapolis or other metro areas 9.

Quality Considerations

Compounded injectables carry inherent sterility risk. The FDA recommends verifying that any 503A pharmacy follows USP 797 standards for sterile compounding 10. Patients should confirm the pharmacy holds current Indiana Board of Pharmacy licensure and can provide a certificate of analysis for its bremelanotide supply.

The Palatin Technologies Savings Card

Palatin Technologies offers a manufacturer savings card that reduces the out-of-pocket cost for commercially insured patients. Eligible patients pay as little as $0 per fill for up to 12 months, with a maximum annual benefit that varies by program year.

Eligibility Rules

The card is restricted to patients with commercial insurance. Government-insured patients (Medicaid, Medicare, Tricare, VA) are excluded per federal anti-kickback statutes 11. Patients must have a valid prescription, be at least 18 years old, and reside in a state where Vyleesi is available. Indiana meets all geographic criteria.

How to Activate

Patients can request the card through their prescriber's office or directly from the manufacturer's patient support program. The card functions as a secondary payer at the pharmacy counter, covering the difference between the insurer's allowed amount and the patient's copay. For patients facing a $200 specialty copay, the card can bring the cost to $0 for the first year 7.

Telehealth Prescribing of Vyleesi in Indiana

Indiana permits telehealth prescribing of Vyleesi. The Indiana General Assembly extended pandemic-era telehealth flexibilities, allowing synchronous video visits to satisfy the prescriber-patient relationship requirement for non-controlled substances.

Practical Workflow

A patient completes an intake questionnaire documenting HSDD symptoms, sexual distress, menstrual status, and medication history. The prescriber conducts a live video consultation, confirms the HSDD diagnosis using DSM-5 criteria, and reviews cardiovascular risk factors (bremelanotide can cause transient blood pressure elevation and heart rate reduction) 1. The prescription is sent electronically to either a retail pharmacy for brand Vyleesi or a 503A compounding pharmacy.

Who Should Avoid Telehealth-Only Prescribing

The FDA label carries a specific warning for patients with uncontrolled hypertension or cardiovascular disease 12. The RECONNECT phase-3 data showed that bremelanotide produced a mean systolic blood pressure increase of approximately 3 mmHg and a mean heart rate decrease of approximately 2 bpm, peaking at 2 to 3 hours post-dose. Patients with a history of cardiovascular events or a resting blood pressure above 160/100 mmHg should have an in-person cardiovascular assessment before starting therapy 13.

Strategies to Reduce Your Out-of-Pocket Cost

Multiple approaches can meaningfully lower what you pay for bremelanotide in Indiana.

Stack Savings Methods

The most cost-effective path for a commercially insured patient: obtain prior authorization, apply the Palatin savings card, and use a specialty pharmacy that offers additional discount layering. For uninsured patients, compounded bremelanotide at $140 per month from a licensed 503A pharmacy represents the lowest verified price point.

Compare Pharmacy Prices

Specialty pharmacy pricing for brand Vyleesi can vary by $50 to $150 per fill in Indiana. Calling at least three pharmacies before filling is a simple step. Hospital-affiliated outpatient pharmacies (such as those within IU Health or Parkview systems) sometimes negotiate lower acquisition costs that translate into reduced cash-pay prices 14.

Consider Flibanserin as an Alternative

Flibanserin (Addyi) is the only other FDA-approved treatment for premenopausal HSDD. It is a daily oral pill priced around $400 to $500 per month at retail, with generic availability expected to lower costs further. A network meta-analysis in The Lancet Psychiatry found both bremelanotide and flibanserin produced statistically significant improvements in satisfying sexual events compared to placebo, though the drugs differ in mechanism, dosing schedule, and side-effect profile 15.

Clinical Efficacy: What You're Paying For

The RECONNECT trial program (two phase-3 studies, combined N=1,247) randomized premenopausal women with HSDD to bremelanotide 1.75 mg or placebo, self-administered subcutaneously as needed before anticipated sexual activity 3.

Primary Outcomes

Bremelanotide-treated patients reported a statistically significant increase in sexual desire score on the FSFI desire domain (mean change +0.6 vs. +0.2 for placebo, P<0.001) and a significant increase in satisfying sexual events per month (+0.5 vs. +0.1) 3. The FDA's medical review noted that approximately 25% of bremelanotide patients achieved a clinically meaningful improvement in desire, compared to 17% on placebo 4.

Safety Profile

The most common adverse events were nausea (40% vs. 1% placebo), flushing (20%), and injection-site reactions (13%). Nausea was dose-limiting in 8% of participants 3. An open-label extension study followed patients for up to 60 weeks and found no new safety signals, with nausea rates decreasing over time as patients adapted to self-injection technique 16.

Cardiovascular Monitoring

As noted above, bremelanotide causes a transient increase in systolic blood pressure. The FDA label recommends against use in patients with uncontrolled hypertension and advises monitoring blood pressure before prescribing 1. A post-marketing study required by the FDA is evaluating long-term cardiovascular outcomes in real-world use 4.

Who Is a Candidate for Bremelanotide in Indiana

The FDA approved bremelanotide specifically for acquired, generalized HSDD in premenopausal women 1. "Acquired" means the low desire developed after a period of normal function. "Generalized" means it occurs across all situations, not only with a specific partner.

Patients must not be postmenopausal (bremelanotide was not studied in that population). The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care algorithm recommends that clinicians rule out medication-induced causes (SSRIs, hormonal contraceptives), relationship distress, and medical conditions before initiating pharmacotherapy 5.

Bremelanotide is contraindicated in patients with uncontrolled hypertension and is not recommended for use with the naltrexone-containing implant because melanocortin-receptor activation may reduce the efficacy of opioid-receptor antagonists 1.